pain relief
- Home
- pain relief
Wellfully set to jump into $9 billion market with FDA registration for their knee pain patch
“How much does it hurt, on a scale of 1-10?” Easily the most frustratingly vague of medical questions due to the huge difference in pain thresholds and perceptions. I don’t know about you, but I’m saving my 10 for childbirth. Nonetheless, when the answer falls beneath an epidural-requiring 10, many of us reach for simple
Read MorePublic
Aussie opioid manufacturer cashed up following $33m sale of facility
While prescription opioids have been getting a pretty bad rap over the past few years amid revelations in the US about a certain Sackler family, they still have a vital role to play in healthcare where good guys like Palla Pharma (ASX: PAL) have strengthened their balance sheet with the sale of their manufacturing facility
Read MorePublic
Could this pharma company hold the answer to overuse of opioids?
Pain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a
Read MorePublic
Q&A: Paradigm to answer FDA questions to achieve Investigational New Drug status
The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate
Read MorePublic
Medical Developments gains approval to commence Penthrox trials in China
Australian pharmaceuticals manufacturer Medical Developments International (ASX: MVP) has secured approval from the Chinese National Medical Product Administration (NMPA) to commence bridging trials for Penthrox IND, their green whistle pain reliever. The approval is a major step towards commercialisation of the flagship non-opioid pain reliever in China. “The approval of the Penthrox IND by the
Read MorePublic
Australia’s green whistle pain relief winning over Europeans
Carried and administered by Australian paramedics for decades, the green whistle pain reliever has been on the Australian market for years but clinical trials in Europe have now revealed Penthrox® to be a superior pain relief product than traditional treatments of morphine (IV), paracetamol, ketoprofen and NSAIDS. Marketed as Penthrox® with the key ingredient of
Read MorePublic